Not Yet Recruiting PHASE2 INTERVENTIONAL 2-arm
NCT06944470
JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLC
JS207 (Anti-PD-1/VEGF Bispecific Antibody) Combined With Platinum-based Doublet Chemotherapy in Subjects With Stage II-III Non-small Cell Lung Cancer
Sponsor: Shanghai Junshi Bioscience Co., Ltd.
Conditions
NSCLC
Interventions
JS207 Paclitaxel + Carboplatin/cisplatin for squamous cell carcinoma and pemetrexed + carboplatin/cisplatin for non-squamous cell carcinoma Radiochemotherapy surgery
Updated 1 time since 2025 Last updated: Apr 23, 2025 Started: Apr 20, 2025 Primary completion: Sep 30, 2026 Completion: Dec 31, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A PHASE2 clinical study on NSCLC, this trial is actively recruiting participants. The trial is conducted by Shanghai Junshi Bioscience Co., Ltd. and has accumulated 1 data snapshot since 2025. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
1 version recorded Not Yet Recruiting — PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Shanghai Junshi Bioscience Co., Ltd.
Data source: Shanghai Junshi Bioscience Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .